Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

How FTSE All-Share trust CT Healthcare Trust (LSE:CTHT) has fared under its absolute return strategy

CTHT (LSE:CTHT) is a constituent of the FTSE All-Shareindexand sits in the financials sector as anInvestmenttrust, within the Healthcare & Biotechnology category of the Association of Investment Companies (AIC). Columbia Threadneedle took over on 5 March 2026, and the AIC names Kosta Kleyman as …

Ankur Sharma | 04 November 2026

Why GlobalData is rebuilding in the FTSE All-Share after its September (LSE:DATA) profit warning

No new trading statement has appeared since half-year results on 14 September. The latest filing, on 2 November, was a routine notice showing 705,528,818 ordinary shares and voting rights as at 30 October, with none held in treasury.

Ankur Sharma | 04 November 2026

Why Oxford Biomedica (LSE:OXB) Is in Focus on 4 November 2026: London Stock Market Outlook and Next Catalysts

The biotechnology servicesBusinessfocuses on viral-vector development and manufacturing. Contract timing, capacity utilisation and partner programmes matter toRevenuevisibility. The appearance of a share in a market watchlist does not by itself establish that a new company-specific catalyst occurred on Wednesday. The more useful question is …

Ankur Sharma | 04 November 2026

Why RTW Biotech Opportunities (LSE:RTW) Is in Focus on 4 November 2026: London Stock Market Outlook and Next Catalysts

RTW Biotech Opportunities is being assessed against its sector backdrop, with particular attention to the ability of itsBusinessmodel to protect margins, generate cash and fund growth without excessive balance-sheet risk. The appearance of a share in a market watchlist does not by itself establish …

Ankur Sharma | 04 November 2026

How Has NIOX Group's (LSE:NIOX) £12.5m Tender Offer Changed Its Capital Position

The company offered to buy up to 15,625,000 shares at 80p each, roughly 3.7% of its share capital. (LSE:NIOX) Shareholders validly tendered 215,151,513 shares, equal to 51.1% of the shares in issue at 29 September. On our calculation, that is close to 14 times …

Ankur Sharma | 04 November 2026

Why AstraZeneca PLC (LSE:AZN) Is in Focus on 4 November 2026: FTSE 100 Investors Watch the Next Catalyst

For AstraZeneca PLC, there is no confirmed standalone catalyst in the available same-day market coverage. Attention is therefore best explained through the interaction of itsBusinessexposure, current market positioning and investors reassessing the prospects for innovative prescription medicines. Treating routine share movement as evidence of …

Ankur Sharma | 04 November 2026

Why Hikma Pharmaceuticals Plc (LSE:HIK) Is in Focus on 4 November 2026: FTSE 100 Investors Watch the Next Catalyst

The most immediate identifiable development is that a trading update was scheduled for 5 November. This givesMarket Participantsa tangible point of reference when comparing current performance with prior expectations. Even so, a daily share-price move can reflect positioning,Liquidityand sector rotation as well as the …

Ankur Sharma | 04 November 2026

What AstraZeneca's (LSE:AZN) third-quarter results mean for a FTSE All-Share healthcare heavyweight

AstraZeneca (LSE:AZN) is a constituent of the FTSE All-Shareindexand sits in the healthcare sector, among general drug manufacturers. According to an AI-generated summary on, third-quarter coreEarnings Per Sharerose 17% to $2.79. The full announcement text was not available on that page, so divisional figures …

Divya Sood | 04 November 2026

Why Biotech Growth Trust (LSE:BIOG) has lost ground since September in the FTSE All-Share

The trust, ticker LSE:BIOG, reported a NAV of 1,503.82p per share at the close on 30 October, according to an AI-generated summary on of a notice published on 2 November. That compares with 1,624.20p in the factsheet for 30 September, a decline of about …

Divya Sood | 04 November 2026

Avacta Group (LSE:AVCT) in Focus as Presentation Of Precision Dual-Payload Candidate Puts London Investors on Alert

The latest corporate development has givenMarket Participantsa fresh reason to assess Avacta Group. Announcements can influence valuation through several channels: an immediate change in expected cash flow, a shift in perceived risk, or a reassessment of management’s ability to execute. In this case, the …

Ankur Sharma | 04 November 2026
Support

Hi! How can we help you today?

Loading…